Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 7Sarcoma 3Liposarcoma, Myxoid 3Sarcoma, Synovial 2Prostatic Neoplasms 2Neurofibrosarcoma 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thymoma 1Small Cell Lung Cancer Limited Stage 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Radiotherapy; Complications 1Radiation Injuries 1Neoplasm Metastasis 1Myosarcoma 1Lymphangiosarcoma 1Lung Neoplasms 1Limited Stage Small Cell Lung Cancer 1Hyperthermia 1Histiocytic Sarcoma 1Endometrial Neoplasms 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Carcinoma In Situ 1

Interventions

pamiparib 1durvalumab 1Radiation Dose Hypofractionation 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Limited Stage Small Cell Lung Cancer × Radiation Dose Hypofractionation × Clear all
NCT05443646 2024-05-07

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
55 enrolled
Thoracic

Limited Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡